SCHEMBL567774

SCHEMBL567774

CC(C)(C)OC(=O)N1CCCN(S(=O)(=O)c2ccc3cnccc3c2)[C@H](CF)C1

nearest known ligand 0.48

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ MMP13 P45452 3/20 0.48
▸ MMP1 P03956 3/20 0.48
▸ MMP9 P14780 3/20 0.48
▸ ADAM17 P78536 1/20 0.45
▸ CYP2C9 P11712 1/20 0.42
▸ MMP3 P08254 1/20 0.41
▸ MMP7 P09237 1/20 0.41
▸ GPR119 Q8TDV5 11/20 0.39
▸ PRMT3 O60678 2/20 0.38
▸ NAMPT P43490 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL567775 1.00 MMP13 (0.48) MMP13MMP1MMP9ADAM17CYP2C9
SCHEMBL567048 0.98 MMP13 (0.46) MMP13MMP1MMP9ADAM17CYP2C9
SCHEMBL567049 0.98 MMP13 (0.46) MMP13MMP1MMP9ADAM17CYP2C9
SCHEMBL568169 0.92 MMP13 (0.49) MMP13MMP1MMP9ADAM17CYP2C9
SCHEMBL568168 0.92 MMP13 (0.49) MMP13MMP1MMP9ADAM17CYP2C9
SCHEMBL568003 0.90 MMP13 (0.47) MMP13MMP1MMP9ADAM17CYP2C9
SCHEMBL568002 0.90 MMP13 (0.47) MMP13MMP1MMP9ADAM17CYP2C9
SCHEMBL567993 0.88 MMP13 (0.51) MMP13MMP1MMP9ADAM17CYP2C9
SCHEMBL567577 0.88 MMP13 (0.51) MMP13MMP1MMP9ADAM17CYP2C9
SCHEMBL567576 0.88 MMP13 (0.51) MMP13MMP1MMP9ADAM17CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2444395-B1 SUBSTITUTED ISOQUINOLINE DERIVATIVE WESTERN THERAPEUTICS INST INC D (JP) 2016-01-06 — — EP disclosed
EP-2444395-B1 SUBSTITUTED ISOQUINOLINE DERIVATIVE WESTERN THERAPEUTICS INST INC D (JP) 2016-01-06 — — EP disclosed
US-8951997-B2 Substituted isoquinoline derivative D. WESTERN THERAPEUTICS INSTITUTE, INC. (JP) 2015-02-10 — — US disclosed
US-8951997-B2 Substituted isoquinoline derivative D. WESTERN THERAPEUTICS INSTITUTE, INC. (JP) 2015-02-10 — — US disclosed
EP-2444395-A1 SUBSTITUTED ISOQUINOLINE DERIVATIVE D. Western Therapeutics Institute, Inc. (JP) 2012-04-25 — — EP disclosed
EP-2444395-A1 SUBSTITUTED ISOQUINOLINE DERIVATIVE D. Western Therapeutics Institute, Inc. (JP) 2012-04-25 — — EP disclosed
US-20120035159-A1 SUBSTITUTED ISOQUINOLINE DERIVATIVE D. WESTERN THERAPEUTICS INSTITUTE, INC (JP) 2012-02-09 — — US disclosed
US-20120035159-A1 SUBSTITUTED ISOQUINOLINE DERIVATIVE D. WESTERN THERAPEUTICS INSTITUTE, INC (JP) 2012-02-09 — — US disclosed
WO-2010146881-A1 SUBSTITUTED ISOQUINOLINE DERIVATIVE 株式会社デ・ウエスタン・セラピテクス研究所 (JP) 2010-12-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120035159-A1 SUBSTITUTED ISOQUINOLINE DERIVATIVE SULT1A1, SULT1E1, SULT2A1 MMP13 4729/4885MMP1 4000/4885MMP9 4791/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback